NYSE$BSX
Boston Scientific Corp · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Boston Scientific's third quarter performance in 2023 reflected strong revenue growth and earnings per share, driven by its category leadership strategy and innovative medical technologies.
Boston Scientific reported net sales of $3.527 billion for Q3 2023, an 11.2% increase year-over-year. GAAP net income attributable to Boston Scientific common stockholders was $505 million, or $0.34 per share, while adjusted EPS reached $0.50. The company's performance was attributed to its global team and differentiated medical technologies.
- Net sales increased by 11.2% on a reported basis, reaching $3.527 billion.
- GAAP net income attributable to Boston Scientific common stockholders was $0.34 per share.
- Adjusted EPS was $0.50 per share, exceeding the guidance range.
- Positive results were announced from the ADVENT pivotal clinical trial of the FARAPULSE™ Pulsed Field Ablation (PFA) System.
Headline financials
Revenue & EPS history
Boston Scientific · Revenue · Quarterly
$3.53B
Revenue by segment
Boston Scientific · $3.53B total across 2 segments · Q3 2023
- Cardiovascular$2.19B+11.6%62.0%
- MedSurg$1.34B+10.6%38.0%
Forward guidance
The company estimates net sales growth for the full year 2023 to be approximately 11 percent on both a reported basis and organic basis. The company estimates EPS on a GAAP basis in a range of $1.00 to $1.04 and estimates adjusted EPS of $1.99 to $2.02. For the fourth quarter of 2023, the company estimates net sales growth to be in a range of approximately 9 to 11 percent on a reported basis, and approximately 8 to 10 percent on an organic basis. The company estimates EPS on a GAAP basis in a range of $0.26 to $0.30 and adjusted EPS of $0.49 to $0.52.
Tailwinds
- Net sales growth for the full year 2023 is estimated to be approximately 11 percent on both a reported basis and organic basis.
- Full year EPS on a GAAP basis is estimated to be in a range of $1.00 to $1.04.
- Full year adjusted EPS is estimated to be $1.99 to $2.02.
- Net sales growth for the fourth quarter of 2023 is estimated to be in a range of approximately 9 to 11 percent on a reported basis.
- Fourth quarter organic net sales growth is expected to be approximately 8 to 10 percent.
Headwinds
- The company's estimates are based on assumptions and are subject to risks and uncertainties.
- The estimates exclude the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures.
- The estimates exclude certain charges (credits).
- Future U.S. and global economic conditions could affect the company's ability to implement its business strategy.
- Manufacturing, distribution and supply chain disruptions and cost increases could affect the company's performance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+0.8%
Avg return
30 days after
64%
47 / 73 earnings
Positive
+14.0%
Q2 2013
Best reaction
-17.4%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.0% | +0.7% | -3.0% | |
| Q4 2025 | -17.4% | -19.1% | -22.1% | |
| Q3 2025 | +4.0% | +2.5% | -3.0% | |
| Q2 2025 | +0.5% | -1.9% | +0.6% | |
| Q1 2025 | +4.0% | +7.5% | +9.9% | |
| Q4 2024 | +1.4% | +2.5% | -4.3% | |
| Q3 2024 | -3.3% | -3.7% | +2.3% | |
| Q2 2024 | -5.5% | -3.8% | +0.7% | |
| Q1 2024 | +6.2% | +5.1% | +9.6% | |
| Q4 2023 | +5.5% | +4.9% | +9.3% | |
| Q3 2023 | -0.9% | +2.4% | +11.3% | |
| Q2 2023 | -1.4% | -1.0% | -3.1% | |
| Q1 2023 | +1.8% | +3.3% | -0.1% | |
| Q4 2022 | +3.9% | +3.0% | +3.4% | |
| Q3 2022 | +0.7% | +4.4% | +6.9% | |
| Q2 2022 | +8.4% | +8.1% | +6.7% | |
| Q1 2022 | +0.3% | -2.3% | -3.3% | |
| Q4 2021 | -2.0% | -1.4% | +1.1% | |
| Q3 2021 | -2.4% | -3.4% | -13.0% | |
| Q2 2021 | +3.3% | +3.7% | +1.6% | |
| Q1 2021 | +4.0% | +2.9% | +0.3% | |
| Q4 2020 | +5.8% | +8.0% | +7.9% | |
| Q3 2020 | -7.1% | -4.2% | -6.8% | |
| Q2 2020 | +1.8% | -0.7% | +7.2% | |
| Q1 2020 | +4.3% | -0.3% | +5.7% | |
| Q4 2019 | +0.3% | -1.5% | -12.3% | |
| Q3 2019 | +6.2% | +8.9% | +9.6% | |
| Q2 2019 | -2.0% | -1.4% | -4.0% | |
| Q1 2019 | +2.9% | +2.3% | +7.2% | |
| Q4 2018 | +2.9% | +4.1% | +4.7% | |
| Q3 2018 | +1.0% | -1.8% | -3.4% | |
| Q2 2018 | +2.3% | -1.9% | +3.4% | |
| Q1 2018 | +3.3% | +0.8% | +6.4% | |
| Q4 2017 | -2.0% | -4.4% | -4.3% | |
| Q3 2017 | -3.7% | -5.0% | -3.2% | |
| Q2 2017 | -1.5% | -3.4% | -2.6% | |
| Q1 2017 | +1.6% | +2.4% | +5.2% | |
| Q4 2016 | +5.3% | +5.3% | +4.3% | |
| Q3 2016 | -4.2% | -2.0% | -5.7% | |
| Q2 2016 | +2.6% | +2.2% | +1.3% | |
| Q1 2016 | +10.9% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +8.1% | — | — | |
| Q2 2015 | -3.7% | — | — | |
| Q1 2015 | -2.2% | — | — | |
| Q4 2014 | +3.3% | — | — | |
| Q3 2014 | +5.7% | — | — | |
| Q2 2014 | +0.7% | — | — | |
| Q1 2014 | -7.1% | — | — | |
| Q4 2013 | -1.9% | — | — | |
| Q3 2013 | -5.5% | — | — | |
| Q2 2013 | +14.0% | — | — | |
| Q1 2013 | +1.2% | — | — | |
| Q4 2012 | +6.6% | — | — | |
| Q3 2012 | -7.1% | — | — | |
| Q2 2012 | -2.1% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2011 | +0.2% | — | — | |
| Q3 2011 | -0.5% | — | — | |
| Q2 2011 | -6.1% | — | — | |
| Q1 2011 | -1.5% | — | — | |
| Q4 2010 | +6.2% | — | — | |
| Q3 2010 | +4.6% | — | — | |
| Q2 2010 | +0.9% | — | — | |
| Q1 2009 | -5.6% | — | — | |
| Q1 2010 | -0.3% | — | — | |
| Q4 2007 | +0.5% | — | — | |
| Q4 2009 | +0.5% | — | — | |
| Q3 2009 | +3.2% | — | — | |
| Q3 2008 | +3.2% | — | — | |
| Q4 2008 | +1.3% | — | — | |
| Q2 2009 | +1.3% | — | — | |
| Q2 2008 | +1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro